Natural killer cell activity in monoclonal gammopathies: Relation to disease activity (Q67674400)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

title

Natural killer cell activity in monoclonal gammopathies: relation to disease activity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

Natural killer cell activity in monoclonal gammopathies: Relation to disease activity (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

2 November 2022

author name string

A. Osterborg

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699786

2 November 2022

B. Nilsson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699786

2 November 2022

M. Björkholm

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699786

2 November 2022

G. Holm

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699786

2 November 2022

H. Mellstedt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699786

2 November 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1699786

2 November 2022

publication date

1 September 1990

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

16 September 2019

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0609.1990.tb00443.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1990.tb00443.x/fullpdf

2 November 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

European Journal of Haematology

2 November 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

volume

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

page(s)

153-157

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

Cytotoxic lymphocytes from normal donors. A functional marker of human non-T lymphocytes

16 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

„Natural”︁ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype

2 November 2022

2

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells

2 November 2022

3

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets

2 November 2022

5

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes

2 November 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Distribution of natural killer cell activity in peripheral blood, cord blood, thymus, lymph nodes, and spleen and the effect of in vitro treatment with interferon preparation

2 November 2022

9

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

The biology of the human natural killer cell

2 November 2022

10

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Spontaneous human lymphocyte-mediated cytotoxicity againts tumour target cells. I. The effect of malignant disease

2 November 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Multiple myeloma, Waldenström's macroglobulinemia, and benign monoclonal gammopathy: characteristics of the B cell clone, immunoregulatory cell populations and clinical implications.

2 November 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

NK and T cell subsets regulate antibody production by human in vivo antigen-induced lymphoblastoid B cells

2 November 2022

13

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Intermittent melphalan and prednisolone therapy in plasma cell myeloma

2 November 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

2 November 2022

16

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III--a randomized study from MGCS

2 November 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults

2 November 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma

2 November 2022

19

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Monoclonal blood lymphocytes in benign monoclonal gammopathy and multiple myeloma in relation to clinical stage

2 November 2022

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

T Cells in Monoclonal Gammopathies

2 November 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smouldering leukemia

2 November 2022

24

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Natural killer activity and antibody-dependent cell-mediated cytotoxicity in multiple myeloma

2 November 2022

25

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Natural killer cell activity in patients with multiple myeloma

2 November 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

B and T lymphocytic populations and subpopulations and natural killer cells (NK) in blood of patients with myeloma and with monoclonal gammopathy of undetermined significance (MGUS)

2 November 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Strong natural killer (NK) cell activity in bone marrow of myeloma patients: accelerated maturation of bone marrow NK cells and their interaction with other bone marrow cells

2 November 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol

2 November 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon-alpha

2 November 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1600-0609.1990.TB00443.X

2 November 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1699786%20AND%20SRC:MED&resulttype=core&format=json

16 September 2019

1 reference